IPO Timeline Raw facts
Company Overview
| Stock Name | Xuanzhubio-B |
|---|---|
| Stock Code | 02575 |
| Company Full Name | Xuanzhu Biopharmaceutical Co., Ltd. |
| Industry | Biotech & Pharma |
| Principal Activities | severe disease that is characterized by liver cirrhosis, fibrosis, and eventually failure and an increased risk of liver cancer |
| Listing Date | 2025-10-15 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18A |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 203C507 Beijing-Tianjin-Hebei Collaborative Innovation Demonstration Park No. 769 Taihang Street, Hi-Tech District Shijiazhuang, Hebei Province PRC Head Office and Principal Place of 2107, Building 2 |
| Business Address (Hong Kong) | 灣仔 皇后大道東183號 合和中心 46樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | xuanzhubio.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | Computershare Hong Kong Investor |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 11.60 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 5,800 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2025-10-06 to 2025-10-10 |
| Global Offering Shares | 67,333,500 shares |
| HK Public Offer Shares (Initial) | 6,733,500 shares (10.0%) |
| Public Offer Lots (Initial) | 13,467lots (Pool A6,733lots,Pool B6,734lots) |
| International Placing Shares (Initial) | 60,600,000 shares (90.0%) |
| Offer Ratio | ~13.0% |
| Total Shares Post-IPO | 517,947,790 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 9.8% |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 781,068,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 5,800 |
| 2 lots | 1,000 | HK$ 11,600 |
| 3 lots | 1,500 | HK$ 17,400 |
| 4 lots | 2,000 | HK$ 23,200 |
| 5 lots | 2,500 | HK$ 29,000 |
| 6 lots | 3,000 | HK$ 34,800 |
| 7 lots | 3,500 | HK$ 40,600 |
| 8 lots | 4,000 | HK$ 46,400 |
| 9 lots | 4,500 | HK$ 52,200 |
| 10 lots | 5,000 | HK$ 58,000 |
| 12 lots | 6,000 | HK$ 69,600 |
| 14 lots | 7,000 | HK$ 81,200 |
| 16 lots | 8,000 | HK$ 92,800 |
| 18 lots | 9,000 | HK$ 104,400 |
| 20 lots | 10,000 | HK$ 116,000 |
| 30 lots | 15,000 | HK$ 174,000 |
| 40 lots | 20,000 | HK$ 232,000 |
| 50 lots | 25,000 | HK$ 290,000 |
| 60 lots | 30,000 | HK$ 348,000 |
| 70 lots | 35,000 | HK$ 406,000 |
| 80 lots | 40,000 | HK$ 464,000 |
| 90 lots | 45,000 | HK$ 522,000 |
| 100 lots | 50,000 | HK$ 580,000 |
| 120 lots | 60,000 | HK$ 696,000 |
| 140 lots | 70,000 | HK$ 812,000 |
| 160 lots | 80,000 | HK$ 928,000 |
| 180 lots | 90,000 | HK$ 1,044,000 |
| 200 lots | 100,000 | HK$ 1,160,000 |
| 400 lots | 200,000 | HK$ 2,320,000 |
| 600 lots | 300,000 | HK$ 3,480,000 |
| 800 lots | 400,000 | HK$ 4,640,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 500,000 | HK$ 5,800,000 |
| 1,200 lots | 600,000 | HK$ 6,960,000 |
| 1,400 lots | 700,000 | HK$ 8,120,000 |
| 1,600 lots | 800,000 | HK$ 9,280,000 |
| 1,800 lots | 900,000 | HK$ 10,440,000 |
| 2,000 lots | 1,000,000 | HK$ 11,600,000 |
| 3,000 lots | 1,500,000 | HK$ 17,400,000 |
| 4,000 lots | 2,000,000 | HK$ 23,200,000 |
| 6,733 lots | 3,366,500 | HK$ 39,051,400 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 12.43B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 6,008,194,364 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 1,864,143,153 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB 556.4 million |
| Period-End Cash Balance | RMB 135.25 million |
| Listing Expenses | ~HK$ 80,100,000 |
| Listing Expenses / Funds Raised | ~10.3% |
| Total Pre-IPO Investment | approximately RMB 1,600 million |
| First Day Close | HK$ 26.3 |
|---|---|
| First Day Open | HK$ 29.46 |
| First Day Change | 126.72% |
| First Day Volume | 14744300.0 |
| First Day Turnover | 429530000.0 |
| Use of Proceeds | 1、約45.0%或315.4百萬港元將用于我們核心產品(即KBP-3571、XZP-3287及 XZP-3621)的研究及開發;
2、約14.0%或98.1百萬港元將用于我們關鍵產品(即KM602、KM501、 XZP-7797及XZP-6924)的研發;
3、約 11.0% 或 77.1 百萬港元將用于為其他候選藥物(包括 XZB-0004、 XZP-5610、XZP-6019及XZP-6877)的研發撥資;
4、約20.0%或140.2百萬港元將被分配用于增強我們的商業化及市場營銷能力;
5、約10.0%或70.1百萬港元將用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
凯易律师事务所 方达律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
欧华律师事务所 竞天公诚律师事务所 |
| Auditor and Reporting Accountant | 安永会计师事务所 |
| Industry Advisor | 灼识行业咨询有限公司 |
| Compliance Advisor | 第一上海融资有限公司 CE AES612 |
| Receiving Banks |
招商永隆银行有限公司 中信银行(国际)有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 德诺瑞朗十五期 | 76,600,000 HKD | 6,603,000 | 9.81% | 1.27% | 6 months | 2026-04-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Ms. Xu Yanjun | Ms. Xu Yanjun |
| Company Secretary | Mr. He Chengming | Mr. He Chengming |
| Executive Director | 徐艳君 | Xu Yanjun |
| Non-Executive Director | 李惠英 | Li Huiying |
| Independent Non-Executive Director | 刘硕 | Liu Shuo |
| Executive Director | 李嘉逵 | Li Jia Kui |
| Non-Executive Director | 尉丽峰 | Yu Lifeng |
| Independent Non-Executive Director | 王宇 | Wang Yu |
| Executive Director | 史澂空 | Shih |
| Non-Executive Director | 陈燕玲 | Chen Yanling |
| Independent Non-Executive Director | 范智超 | Fan Chi Chiu |
| Independent Non-Executive Director | 卢本玉 | Lu Benyu |
| Independent Non-Executive Director | 王晓平 | Wang Xiaoping |
| Independent Non-Executive Director | 岳鑫 | Yue Xin |
Major Shareholders
| Major Shareholders & Holdings | Immediately after completion of the Global Offering and the conversion of the Unlisted Shares into H Shares, Sihuan Pharmaceutical will hold 254,451,414 Unlisted Shares, representing 49.13% of the total issued share capital; SDIC China Merchants Investment Management Co., Ltd. will hold 93,377,320 Unlisted Shares, representing 18.03%; Mr. Che Yu Xuan will hold 36,049,144 H Shares, representing 6.96%; Ms. Xu will hold 4,714,400 H Shares and, through Beihai Jixin, will hold 8,466,510 H Shares, representing 2.54% in aggregate; Mr. Zhu Xiaodong will hold 13,039,600 H Shares, representing 2.52%; and Mr. Hou Deyan will hold 12,315,700 H Shares, representing 2.38%. |
|---|
Market Sentiment
The IPO attracted overwhelming demand, with an oversubscription ratio of 4,908x indicating extreme retail frenzy. However, the 0% hit rate under Mechanism B with no clawback means virtually no public applicants received allocations, highlighting a very tight supply. Final pricing details are not provided, but such demand often leads to pricing at the upper end. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
At the A/B boundary, 甲尾 (last A-tier) expected 0.138 lots while 乙头 (first B-tier) expected only 0.1509 lots, a marginal gain for a significantly larger capital commitment. This creates a highly inefficient tier structure, where the additional margin cost for B-head far outweighs the negligible allocation increase. Broker fee efficiency is severely compromised across all tiers given the sub-one-lot expected allocations. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
With a 0% hit rate and zero recorded holders, demographic data such as mainland participation, gender, or regional distribution is unavailable. In such extreme oversubscriptions, the absence of allocation data makes it impossible to analyze applicant demographics meaningfully. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




